Faculty

Ray Matthews

Professor of Clinical Medicine;Director of Interventional Cardiology and Catheterization Laboratories;Director, CVI Outreach & Network Development

Medicine

HCC 322 Health Sciences Campus Los Angeles

Contact

+1 323 442 6130

raymatth@usc.edu

Division of Cardiovascular Medicine, Keck School of Medicine of USC: Golden Apple Award for Outstanding Teaching, 2013

American Heart Association : First Place, Clinical Division, Laverne Titus Young Investigator Competition, 1987

Harbor-UCLA Medical Center: Distinguished Teaching Award, 1987

American Heart Association: Group Investigator Award, 1986

The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study) Cardiovasc Revasc Med. 2023 Apr 29. . View in PubMed

Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysis Am J Physiol Heart Circ Physiol. 2022 09 01; 323(3):H559-H568. . View in PubMed

Factors Associated With the Use of Bare Metal Stents in Patients With ST Elevation Myocardial Infarction Cardiovasc Revasc Med. 2020 12; 21(12):1489-1492. . View in PubMed

Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial Lancet. 2020 09 05; 396(10252):669-683. . View in PubMed

In-Hospital Outcomes of Rotational Atherectomy in High-Risk Patients With Severely Calcified Left Main Coronary Artery Disease: A Single-Center Experience J Invasive Cardiol. 2019 04; 31(4):101-106. . View in PubMed

Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS) Cardiovasc Revasc Med. 2018 Apr - May; 19(3 Pt B):319-323. . View in PubMed

Long-term outcomes of drug-eluting stents versus bare metal stents in saphenous vein graft interventionsEvidence from a meta-analysis of randomized controlled trials. Cardiovasc Revasc Med. 2018 12; 19(8):951-955. . View in PubMed

Incidence and treatment of severe primary mitral regurgitation in contemporary clinical practice Cardiovasc Revasc Med. 2018 12; 19(8):960-963. . View in PubMed

Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia Cardiovasc Revasc Med. 2018 07; 19(5 Pt A):516-520. . View in PubMed

Comparison of devices used in carotid artery stenting: A vascular quality initiative analysis of commonly used carotid stents and embolic protection devices Catheter Cardiovasc Interv. 2018 10 01; 92(4):743-749. . View in PubMed

Comparison of Outcomes of Percutaneous Coronary Intervention on Native Coronary Arteries Versus on Saphenous Venous Aorta Coronary Conduits in Patients With Low Left Ventricular Ejection Fraction and Impella Device Implantation Achieved or Attempted (from the PROTECT II Randomized Trial and the cVAD Registry) Am J Cardiol. 2018 09 15; 122(6):966-972. . View in PubMed

Association of elevated triglycerides and acute myocardial infarction in young Hispanics Cardiovasc Revasc Med. 2016 Dec; 17(8):510-514. . View in PubMed

Impact of Surgical Consultation on Outcomes in Hemodynamically Supported High-Risk Percutaneous Coronary Intervention: Insights From PROTECT II Randomized Study J Invasive Cardiol. 2016 May; 28(5):187-92. . View in PubMed

Same-day discharge after coronary stenting and femoral artery device closure: A randomized study in stable and low-risk acute coronary syndrome patients Cardiovasc Revasc Med. 2016 Apr-May; 17(3):155-61. . View in PubMed

Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience Am Heart J. 2015 Nov; 170(5):872-9. . View in PubMed

The Reply Am J Med. 2015 Sep; 128(9):e35. . View in PubMed

Early repolarization masquerading as STEMI Am J Med. 2014 Nov; 127(11):e1-e2. . View in PubMed

Design and rationale of the ANALYZE ST study: a prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patientsAm Heart J. 2014 Oct; 168(4):424-429. e1. . View in PubMed

African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention Cardiovasc Revasc Med. 2014 Jun; 15(4):214-8. . View in PubMed

Predictors of reperfusion delay in patients with ST elevation myocardial infarction self-transported to the hospital (from the American Heart Association's Mission: Lifeline Program) Am J Cardiol. 2014 Mar 01; 113(5):798-802. . View in PubMed

Use of regadenoson for measurement of fractional flow reserve Catheter Cardiovasc Interv. 2014 Feb 15; 83(3):369-74. . View in PubMed

Utility of fluoroscopy in teaching trainees groin puncture technique J Invasive Cardiol. 2014 Jan; 26(1):18-20. . View in PubMed

Time of day variation in door-to-balloon time for STEMI patients in Los Angeles County: does time of day make a difference? Acute Card Care. 2013 Sep; 15(3):52-7.. View in PubMed

Catheter intervention in structural heart diseasePreface. Cardiol Clin. 2013 Aug; 31(3):ix-x. . View in PubMed

Transcatheter aortic valve replacement with CoreValve Cardiol Clin. 2013 Aug; 31(3):351-61. . View in PubMed

Anomalous coronary arteries: cardiovascular computed tomographic angiography for surgical decisions and planning World J Pediatr Congenit Heart Surg. 2013 Apr; 4(2):142-54. . View in PubMed

Percutaneous left ventricular support for high-risk PCI and cardiogenic shock: who gets what? Cardiovasc Revasc Med. 2012 Mar-Apr; 13(2):101-5.. View in PubMed

Percutaneous devices to support the left ventricle Expert Rev Med Devices. 2011 Nov; 8(6):681-94. . View in PubMed

Double-stent method: an alternative technique to treat coronary artery aneurysms Catheter Cardiovasc Interv. 2011 Jun 01; 77(7):1036-41. . View in PubMed

Use of drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction J Invasive Cardiol. 2009 Nov; 21(11):E206-12. . View in PubMed

Intravascular ultrasound-guided central vein angioplasty and stenting without the use of radiographic contrast agents J Clin Ultrasound. 2008 May; 36(4):254-6. . View in PubMed

Percutaneous left atrial appendage obliteration JACC Cardiovasc Imaging. 2008 Jan; 1(1):92-3. . View in PubMed

Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial Am Heart J. 2005 Dec; 150(6):1163-70. . View in PubMed

Images in cardiology: Electron beam angiography of percutaneous atrial septal defect closure Clin Cardiol. 2004 Dec; 27(12):702. . View in PubMed

Dr Matthews was recruited in 2007 to build and lead the section of interventional cardiology at USC. He has 35 years of experience in the catheter based treatment of a wide variety of cardiac disease states. He is well recognized as a pioneer in the performance of coronary interventions in patients too ill for bypass surgery, by using temporary ventricular assist devices during coronary stenting. Dr Mathews was one of the first cardiologists to close congenital heart defects percutaneously in Los Angeles and has since accumulated a large experience in ASD, VSD and PFO closure. Dr Matthews developed a structural heart program at USC over the past decade where he helped USC lead in the early development of TAVR procedures and now has performed well over 1000 of these procedures himself. Through his leadership, USC now has robust programs to percutaneously replace aortic, pulmonic and mitral valves as well.

Dr Matthews maintains a large practice of patients referred with cardiac abnormalities too challenging for community practitioners. He is also a dedicated teacher and scientist. He has trained over 80 interventional cardiologists who have gone on to successful practices all over the US and the world. He is a sought after speaker on the topic of structural heart disease and high risk coronary intervention. He is also involved in research projects to develop implantable sensors that are patient operated to detect heart failure at home and synthetically produced artificial TAVR valves. Dr Matthews continues to innovate and lead in interventional cardiology assisting in the development of numerous medical devices to facilitate the performance of cardiac procedures less invasively, safely and with excellent outcomes.